TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

TRINITY BIOTECH PLC

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026

$8.19+0.16 (+1.99%)

Close on Oct 19, 2026

Community

Notes and questions about Trinity Biotech from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Trinity Biotech's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Jul 24, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TRIB.

Revenue growth-28.9% · median 10.4%

Gross margin38.6% · median 40.3%

Operating margin-36.1% · median -33.5%

Net margin-85.4% · median -38.8%

Advertisement
300 × 250